Misoprostol for Management of Women With an Incomplete Miscarriage

• Status: Not yet recruiting
• Trial end date: 2023-03-31
• Target enrollment: 0
• Participant gender: Female

Summary

Miscarriage is defined as the spontaneous loss of a pregnancy before 24 weeks gestation, that is, before fetal viability. The clinical signs of miscarriage are usually vaginal bleeding associated with abdominal pain and cramping. The miscarriage is named 'complete' or 'incomplete' according to whether or not tissues are retained in the uterus. If a woman has minimal bleeding but her cervix is closed, this is known as a 'threatened miscarriage. However; if the pregnancy is still inside the uterus but the cervix is open, this is described as an 'inevitable miscarriage', which it will not usually be possible to save the fetus.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aswan University Hospital
• Treatments: Misoprostol

Criteria

Inclusion Criteria:

• Women with confirmed incomplete induced miscarriage, less than 12 weeks' gestation.

• No known allergy to misoprostol.

• Women who will be hemodynamically stable.

• Good access to emergency facilities

Exclusion Criteria:

• Women with signs of severe infection ( fever > 38°)

• Women with severe vaginal bleeding

• Women are known to have allergies to prostaglandins

• Severe abdominal pain requiring immediate intervention